You are here » Media » Press releases

Press Releases

April 28, 2015

Lausanne, 29 April 2015 – Galderma, a global leader committed to dermatology and skin health, has announced its entry into the nutraceutical market through the acquisition of certain assets of Inneov Group. Relevant Inneov products are marketed under the brand names Nutri-Care D, Duocap, Densilogy, Densilogy Men, Fermete, Fermete Aox, Firmness, Pre-Hyaluron 465, Solar and Sun Sensitivity.

 “The nutraceutical category has a strong fit with our Self-medication business.  Many of the Innéov brands are complementary to our existing portfolio of skin health medical solutions,” said Stuart Raetzman, Chief Executive Officer of Galderma. “We look forward to expanding our range of nutraceutical products and to serving consumers’ needs around the world.”

“Partnering with healthcare professionals to meet the needs of dermatology patients is Galderma’s unique focus” added Janusz Czernielewski, Chief Medical Officer of Galderma. “Backed by science and clinical evidence and recommended by healthcare professionals, the nutraceutical products can play an important role in the health of skin, hair and nails throughout the course of people’s lives.”

On April 24 Nestlé Skin Health announced that Galderma, its company focused on medical solutions, had entered into an agreement under which it will acquire certain assets of Innéov Group, contingent upon competition authority clearance.

About Galderma

Galderma is committed to delivering innovative medical solutions to meet the dermatological needs of people throughout their lifetime while serving healthcare professionals around the world. The Company’s extensive product portfolio is available in 80 countries and treats a range of dermatological conditions including: acne, rosacea, nail mycosis, psoriasis & steroid-responsive dermatoses, pigmentary disorders, skin cancer and medical solutions for skin senescence.  Strategic brands include Epiduo, Oracea, Differin, Mirvaso, Soolantra, Tri-Luma, Loceryl, Benzac, Cetaphil, Excipial, Daylong, Metvix, Azzalure/Dysport, Restylane and Emervel.

 

Media Contact

Sebastien Cros

+33 1 5886 45 92

media@galderma.com

Posted in: Press release

Follow us Follow us on twitter Follow us on Linkedin

Corporate responsibility

Growing a responsible dermatological community

Discover some of the positive initiatives we are involved in across the world

Read

Video

We are committed

See all videos